ZUBIQO.
AI & MLCryptoFinanceBig TechAI Models
CybersecurityGamingEVs & Clean EnergyRoboticsAerospaceBiotech & Health
Enterprise
ZUBIQO.

High-magnitude intelligence briefs for the tech and finance sectors. Zero fluff. Maximum signal.

[email protected]
X (Twitter)ThreadsTelegramBlueskyMastodon

Sections

  • AI & ML
  • Crypto
  • Finance
  • Big Tech
  • Cybersecurity
  • Gaming
  • EVs & Clean Energy
  • Robotics
  • Aerospace
  • Biotech & Health

Publication

  • About Us
  • Editorial Ethics
  • Partner With Us
  • Contact Us

Tools

  • AI Models Pricing

Legal

  • Privacy Policy
  • Terms of Service
  • Fair Use & DMCA

Disclaimer:Zubiqo Intelligence operates as a technology-enabled news and research publication under human editorial oversight. The news briefs, market analysis, "Magnitude Scores", and "Community Sentiment" metrics provided on this platform are strictly for informational and educational purposes only. They do not constitute financial, legal, investment, or trading advice. Cryptocurrencies and financial markets are highly volatile; always conduct your own research and consult with a licensed professional before making any investment decisions. By using this site, you agree to our Terms of Service.

© 2026 Zubiqo Intelligence. All rights reserved.

Search Intelligence

Results for: "radiopharma"

Telix Acquires ITM in $2.35B Deal to Dominate Radiopharmaceutical Supply Chain
Biotech/Health
about 2 hours ago•1 min read

Telix Acquires ITM in $2.35B Deal to Dominate Radiopharmaceutical Supply Chain

Zubiqo Take

"Locking up an independent isotope manufacturer for $2.35B proves that in modern biotech, owning the physical supply chain is vastly more valuable than just owning the IP."

BullishMag 8
Pharmaceutical Technology
Curium strikes up to $8B deal for radiopharma rival Lantheus
Urgent
Finance
about 2 months ago•1 min read

Curium strikes up to $8B deal for radiopharma rival Lantheus

Zubiqo Take

"Taking Lantheus private is just a brute-force play to own the entire nuclear medicine supply chain without answering to public shareholders."

BullishMag 10
Fierce Biotech